Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Eric Wu

Concepts (464)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Health Care Costs
31
2022
425
4.040
 Why?
Hyperkalemia
4
2021
36
2.460
 Why?
Everolimus
10
2016
112
2.280
 Why?
Health Resources
10
2026
130
2.270
 Why?
Cost of Illness
13
2022
324
1.970
 Why?
Health Services
11
2016
113
1.460
 Why?
Breast Neoplasms
16
2018
2382
1.450
 Why?
Antineoplastic Agents
20
2018
2214
1.400
 Why?
Citalopram
6
2012
32
1.190
 Why?
Receptors, Antigen, T-Cell
4
2021
673
1.120
 Why?
Health Expenditures
9
2020
194
1.110
 Why?
Receptors, Estrogen
3
2015
401
1.110
 Why?
Medication Adherence
4
2015
540
1.030
 Why?
Psoriasis
5
2018
115
0.990
 Why?
Immunotherapy, Adoptive
2
2020
342
0.970
 Why?
Insurance Claim Review
18
2017
83
0.950
 Why?
Practice Patterns, Physicians'
6
2018
1371
0.940
 Why?
United States
52
2022
16098
0.920
 Why?
Hepatitis C, Chronic
3
2019
153
0.910
 Why?
Pyrimidines
7
2014
530
0.870
 Why?
Drug Substitution
3
2019
63
0.860
 Why?
Renal Insufficiency, Chronic
3
2021
668
0.860
 Why?
Middle Aged
76
2026
36215
0.850
 Why?
Piperazines
6
2014
375
0.850
 Why?
Biosimilar Pharmaceuticals
2
2022
28
0.850
 Why?
Receptors, Progesterone
2
2015
243
0.810
 Why?
Attention Deficit Disorder with Hyperactivity
4
2012
429
0.780
 Why?
Aged
57
2026
26153
0.770
 Why?
Retrospective Studies
46
2026
17291
0.770
 Why?
Models, Economic
2
2020
61
0.760
 Why?
Comparative Effectiveness Research
3
2012
168
0.750
 Why?
Benzamides
6
2014
226
0.740
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
2014
127
0.740
 Why?
Antifungal Agents
4
2017
151
0.730
 Why?
Humans
123
2026
145474
0.720
 Why?
Cost-Benefit Analysis
15
2022
639
0.710
 Why?
Imatinib Mesylate
7
2014
77
0.700
 Why?
Female
93
2026
78844
0.700
 Why?
Central Nervous System Stimulants
3
2012
185
0.690
 Why?
Lymphoma, Large B-Cell, Diffuse
2
2021
193
0.660
 Why?
Hospital Costs
3
2020
125
0.660
 Why?
Gout
2
2012
34
0.650
 Why?
Rheumatology
1
2022
133
0.650
 Why?
Adult
58
2026
40777
0.640
 Why?
Acidosis
1
2021
105
0.640
 Why?
Male
79
2026
72842
0.630
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
297
0.630
 Why?
Proportional Hazards Models
14
2017
1327
0.620
 Why?
Hypoglycemic Agents
4
2015
1399
0.620
 Why?
Kaplan-Meier Estimate
12
2018
969
0.610
 Why?
Nocturia
1
2019
8
0.610
 Why?
Antineoplastic Combined Chemotherapy Protocols
11
2018
1963
0.600
 Why?
Antibodies, Monoclonal
7
2018
1505
0.600
 Why?
Databases, Factual
13
2021
1490
0.590
 Why?
Prevalence
11
2021
2865
0.580
 Why?
Postmenopause
7
2018
392
0.570
 Why?
Comorbidity
12
2014
1661
0.550
 Why?
Hospitalization
15
2021
2460
0.550
 Why?
Medicare
10
2022
903
0.540
 Why?
Nutrition Surveys
1
2019
279
0.530
 Why?
Proline
2
2015
82
0.530
 Why?
Candida
2
2017
45
0.530
 Why?
Leukemia, Myeloid, Chronic-Phase
2
2014
3
0.520
 Why?
Fluconazole
1
2017
23
0.510
 Why?
Candidemia
1
2017
15
0.510
 Why?
Protein Kinase Inhibitors
5
2014
981
0.510
 Why?
Cardiologists
1
2017
45
0.500
 Why?
Myocardial Perfusion Imaging
1
2017
50
0.500
 Why?
Fees, Pharmaceutical
3
2016
8
0.500
 Why?
Tomography, Emission-Computed, Single-Photon
1
2017
104
0.490
 Why?
Oligopeptides
2
2015
267
0.480
 Why?
Aftercare
2
2021
222
0.480
 Why?
Diabetes Mellitus, Type 2
5
2015
2588
0.470
 Why?
Thrombolytic Therapy
1
2017
164
0.470
 Why?
Cystitis, Interstitial
2
2006
20
0.470
 Why?
Biological Therapy
1
2016
28
0.470
 Why?
Antidepressive Agents, Second-Generation
3
2011
46
0.460
 Why?
Antiviral Agents
3
2019
769
0.460
 Why?
Antirheumatic Agents
2
2016
307
0.460
 Why?
Neoplasm Recurrence, Local
4
2026
1149
0.450
 Why?
Drug Eruptions
1
2015
28
0.450
 Why?
Tissue Plasminogen Activator
1
2017
248
0.440
 Why?
Propylamines
2
2012
11
0.430
 Why?
Costs and Cost Analysis
10
2019
221
0.430
 Why?
Physicians, Primary Care
1
2017
208
0.420
 Why?
Fibrinolytic Agents
1
2017
297
0.420
 Why?
Methylphenidate
2
2012
49
0.420
 Why?
Gastrointestinal Stromal Tumors
1
2014
41
0.420
 Why?
Diphosphonates
2
2012
68
0.410
 Why?
Delivery of Health Care
2
2019
946
0.410
 Why?
Health Care Rationing
2
2016
56
0.410
 Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2008
345
0.410
 Why?
Insulin
3
2015
2512
0.410
 Why?
Patient Acceptance of Health Care
8
2026
881
0.400
 Why?
Anemia
1
2015
191
0.400
 Why?
Brain Ischemia
1
2017
359
0.390
 Why?
Treatment Outcome
24
2021
11772
0.390
 Why?
Imidazoles
2
2012
247
0.390
 Why?
Hypertension
5
2018
1273
0.390
 Why?
Insurance, Health
5
2011
310
0.380
 Why?
Neoplasm Metastasis
8
2018
688
0.380
 Why?
Dextroamphetamine
1
2012
4
0.370
 Why?
Guanfacine
1
2012
5
0.370
 Why?
Aged, 80 and over
14
2020
8333
0.370
 Why?
Antineoplastic Agents, Hormonal
4
2016
193
0.370
 Why?
Pharmacoepidemiology
1
2012
23
0.360
 Why?
Liver Neoplasms
2
2015
776
0.350
 Why?
Attention Deficit and Disruptive Behavior Disorders
1
2012
56
0.350
 Why?
Schizophrenia
2
2006
453
0.350
 Why?
Patient Compliance
3
2011
587
0.350
 Why?
Medicaid
3
2012
467
0.340
 Why?
Pulmonary Embolism
1
2014
241
0.340
 Why?
Drug Delivery Systems
1
2015
381
0.340
 Why?
Drug Costs
6
2015
117
0.340
 Why?
Fumarates
1
2011
10
0.330
 Why?
Disease-Free Survival
7
2019
767
0.330
 Why?
Antibodies, Monoclonal, Humanized
9
2018
992
0.330
 Why?
Drugs, Generic
1
2011
28
0.330
 Why?
Referral and Consultation
1
2017
867
0.320
 Why?
Bone Diseases
1
2011
61
0.320
 Why?
Amides
1
2011
101
0.310
 Why?
Triazoles
4
2016
187
0.310
 Why?
Angiotensin Receptor Antagonists
1
2011
115
0.310
 Why?
Stroke
2
2017
1270
0.300
 Why?
Drug Monitoring
4
2016
401
0.300
 Why?
Venous Thromboembolism
1
2014
328
0.300
 Why?
Angiotensin-Converting Enzyme Inhibitors
1
2011
229
0.300
 Why?
Arthritis, Rheumatoid
2
2016
1180
0.300
 Why?
Tumor Necrosis Factor-alpha
5
2022
1217
0.290
 Why?
Potassium
2
2021
152
0.290
 Why?
Crohn Disease
5
2012
260
0.290
 Why?
Sick Leave
2
2007
16
0.290
 Why?
Heart Failure
3
2020
2326
0.290
 Why?
Diabetes Mellitus
1
2018
1097
0.290
 Why?
Hyperuricemia
1
2009
47
0.290
 Why?
Myelodysplastic Syndromes
2
2021
165
0.280
 Why?
Anticoagulants
1
2014
748
0.280
 Why?
Oligonucleotides
2
2019
153
0.270
 Why?
Absenteeism
2
2005
52
0.270
 Why?
Uric Acid
1
2009
167
0.270
 Why?
Quality of Life
9
2021
3204
0.270
 Why?
Risk Factors
12
2017
10885
0.260
 Why?
Insurance Claim Reporting
2
2007
26
0.260
 Why?
Multiple Myeloma
1
2011
309
0.260
 Why?
Randomized Controlled Trials as Topic
3
2012
1747
0.250
 Why?
Head and Neck Neoplasms
1
2012
561
0.250
 Why?
Physicians
1
2015
955
0.250
 Why?
Hypoglycemia
1
2012
479
0.250
 Why?
Leukemia, Myeloid, Acute
2
2026
686
0.240
 Why?
Health Status Indicators
1
2007
167
0.240
 Why?
Young Adult
14
2026
14218
0.240
 Why?
Drug Therapy, Combination
6
2019
1044
0.240
 Why?
Pentosan Sulfuric Polyester
1
2006
2
0.240
 Why?
Economics, Pharmaceutical
1
2006
10
0.240
 Why?
Drug Resistance, Fungal
2
2017
7
0.230
 Why?
Treatment Failure
3
2017
360
0.230
 Why?
fms-Like Tyrosine Kinase 3
1
2026
51
0.230
 Why?
Endometriosis
2
2017
58
0.220
 Why?
Adolescent
22
2026
22529
0.220
 Why?
Urinary Incontinence
1
2005
65
0.210
 Why?
Diagnostic Errors
1
2006
178
0.210
 Why?
Prostatic Neoplasms
2
2012
978
0.210
 Why?
Nitriles
3
2016
207
0.210
 Why?
Immunoglobulin G
1
2008
892
0.210
 Why?
Recurrence
3
2020
1138
0.200
 Why?
Electronic Health Records
2
2021
1196
0.190
 Why?
Emergency Service, Hospital
4
2021
2381
0.190
 Why?
Protein-Tyrosine Kinases
4
2014
431
0.190
 Why?
Psychotic Disorders
1
2005
189
0.190
 Why?
Antihypertensive Agents
3
2012
519
0.190
 Why?
Molecular Targeted Therapy
3
2015
439
0.190
 Why?
Genetic Therapy
2
2021
316
0.180
 Why?
Thiophenes
2
2014
117
0.180
 Why?
Infliximab
1
2022
111
0.180
 Why?
Delayed-Action Preparations
3
2017
189
0.180
 Why?
Population Surveillance
1
2005
484
0.170
 Why?
Anti-Inflammatory Agents
3
2011
477
0.170
 Why?
Giant Cell Tumor of Tendon Sheath
1
2021
9
0.170
 Why?
Bone Density Conservation Agents
2
2012
82
0.170
 Why?
Gout Suppressants
2
2012
19
0.170
 Why?
Gastritis
1
2022
116
0.170
 Why?
Enteritis
1
2022
104
0.170
 Why?
Carcinoma, Non-Small-Cell Lung
3
2015
1189
0.160
 Why?
Polymerase Chain Reaction
2
2014
1041
0.160
 Why?
Biological Products
2
2016
257
0.160
 Why?
Severity of Illness Index
6
2018
2930
0.160
 Why?
Hemophilia B
1
2021
65
0.160
 Why?
Atomoxetine Hydrochloride
2
2012
8
0.160
 Why?
Antimetabolites, Antineoplastic
1
2021
106
0.160
 Why?
Bronchodilator Agents
2
2011
187
0.160
 Why?
Adenocarcinoma
1
2007
925
0.160
 Why?
Time Factors
5
2017
7123
0.160
 Why?
Voriconazole
2
2016
21
0.150
 Why?
Immunologic Factors
1
2022
260
0.150
 Why?
Eosinophilia
1
2022
223
0.150
 Why?
National Health Programs
1
2019
23
0.150
 Why?
Regression Analysis
4
2012
1001
0.150
 Why?
Technology Assessment, Biomedical
1
2019
44
0.150
 Why?
Muscular Atrophy, Spinal
1
2019
24
0.150
 Why?
Pulmonary Disease, Chronic Obstructive
3
2011
919
0.150
 Why?
Aromatase Inhibitors
2
2018
78
0.150
 Why?
Hemophilia A
1
2021
148
0.150
 Why?
Patient Readmission
2
2017
769
0.150
 Why?
Survival of Motor Neuron 1 Protein
1
2019
11
0.150
 Why?
Atrial Fibrillation
1
2005
558
0.150
 Why?
Health Services Research
1
2021
391
0.150
 Why?
Spinal Muscular Atrophies of Childhood
1
2019
18
0.140
 Why?
Survival Analysis
4
2018
1374
0.140
 Why?
Multivariate Analysis
5
2015
1547
0.140
 Why?
Microbial Sensitivity Tests
2
2017
364
0.140
 Why?
Urologic Neoplasms
1
2018
31
0.140
 Why?
China
2
2021
270
0.140
 Why?
Idiopathic Pulmonary Fibrosis
2
2015
692
0.140
 Why?
Aging
1
2009
1969
0.140
 Why?
Europe
3
2019
418
0.140
 Why?
Vital Capacity
2
2015
292
0.130
 Why?
Polystyrenes
1
2018
38
0.130
 Why?
Managed Care Programs
2
2010
140
0.130
 Why?
Antidepressive Agents
2
2011
242
0.130
 Why?
Chronic Disease
4
2014
1808
0.130
 Why?
Time-to-Treatment
2
2017
251
0.130
 Why?
4-Aminopyridine
1
2017
30
0.130
 Why?
Retreatment
1
2017
79
0.130
 Why?
Overweight
1
2022
614
0.130
 Why?
Thiazoles
2
2014
141
0.130
 Why?
Drug Administration Schedule
4
2013
782
0.120
 Why?
Aspergillosis
1
2016
24
0.120
 Why?
Chemotherapy, Adjuvant
2
2016
423
0.120
 Why?
Patient Preference
1
2019
223
0.120
 Why?
Abiraterone Acetate
1
2016
15
0.120
 Why?
Consumer Behavior
1
2017
69
0.120
 Why?
Administration, Intravenous
1
2017
172
0.120
 Why?
Hysterectomy
1
2017
138
0.120
 Why?
Administrative Claims, Healthcare
1
2016
28
0.120
 Why?
Mental Disorders
1
2005
1163
0.120
 Why?
Prostatic Neoplasms, Castration-Resistant
1
2016
53
0.120
 Why?
Capecitabine
1
2016
56
0.120
 Why?
Trastuzumab
1
2016
118
0.110
 Why?
Disability Evaluation
1
2017
310
0.110
 Why?
Prednisone
1
2016
224
0.110
 Why?
Clinical Protocols
1
2017
280
0.110
 Why?
Androstadienes
1
2015
75
0.110
 Why?
Ki-1 Antigen
1
2015
7
0.110
 Why?
Patient Admission
1
2017
220
0.110
 Why?
International Classification of Diseases
1
2016
150
0.110
 Why?
Patient Discharge
1
2021
992
0.110
 Why?
Waiting Lists
1
2017
266
0.110
 Why?
Logistic Models
2
2014
2134
0.110
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2015
22
0.110
 Why?
Ribavirin
1
2015
81
0.110
 Why?
Drug Interactions
1
2016
405
0.110
 Why?
Ambulatory Care
3
2015
609
0.110
 Why?
Neoplasm Staging
2
2015
1471
0.110
 Why?
California
2
2006
471
0.100
 Why?
Carboplatin
1
2014
162
0.100
 Why?
Heparin, Low-Molecular-Weight
1
2014
37
0.100
 Why?
International Normalized Ratio
1
2014
55
0.100
 Why?
Amphotericin B
1
2014
36
0.100
 Why?
Cytogenetic Analysis
1
2013
33
0.100
 Why?
Recombinant Proteins
1
2017
1368
0.100
 Why?
Japan
3
2021
149
0.100
 Why?
Insurance, Health, Reimbursement
1
2014
98
0.100
 Why?
Models, Theoretical
1
2017
558
0.100
 Why?
Cross-Sectional Studies
3
2019
5904
0.100
 Why?
Follow-Up Studies
5
2015
5423
0.100
 Why?
Drug Prescriptions
1
2015
288
0.100
 Why?
Constipation
1
2014
98
0.100
 Why?
ErbB Receptors
2
2016
635
0.100
 Why?
Paclitaxel
1
2014
257
0.100
 Why?
Morpholines
1
2014
130
0.100
 Why?
Immunoconjugates
1
2015
138
0.100
 Why?
Receptor Protein-Tyrosine Kinases
1
2015
231
0.100
 Why?
Mycoses
1
2014
88
0.100
 Why?
Budgets
1
2012
14
0.090
 Why?
Recovery of Function
1
2017
716
0.090
 Why?
Hodgkin Disease
1
2015
171
0.090
 Why?
Drug Combinations
2
2011
396
0.090
 Why?
Allopurinol
1
2012
70
0.090
 Why?
Cohort Studies
5
2016
6013
0.090
 Why?
Warfarin
1
2014
179
0.090
 Why?
Adalimumab
5
2011
55
0.090
 Why?
Lisdexamfetamine Dimesylate
1
2012
8
0.090
 Why?
Laparoscopy
1
2017
481
0.090
 Why?
New Zealand
1
2012
54
0.090
 Why?
Immunocompromised Host
1
2014
202
0.090
 Why?
Pyridines
1
2016
609
0.090
 Why?
Ethanolamines
1
2012
14
0.090
 Why?
Gastrointestinal Diseases
1
2014
221
0.090
 Why?
Databases as Topic
2
2009
71
0.090
 Why?
Health Status
2
2008
832
0.090
 Why?
Benzopyrans
1
2012
30
0.090
 Why?
Genetic Testing
1
2015
480
0.090
 Why?
Clinical Trials as Topic
2
2019
1061
0.090
 Why?
Estradiol
1
2015
515
0.090
 Why?
Triple Negative Breast Neoplasms
1
2014
218
0.090
 Why?
Florida
1
2012
117
0.090
 Why?
Sulfonylurea Compounds
1
2012
51
0.090
 Why?
Multiple Sclerosis
1
2017
489
0.090
 Why?
Pleural Effusion
1
2012
59
0.090
 Why?
Rivaroxaban
1
2014
271
0.090
 Why?
Surveys and Questionnaires
4
2021
6066
0.090
 Why?
Neurotransmitter Uptake Inhibitors
1
2011
3
0.090
 Why?
North America
1
2012
302
0.090
 Why?
Australia
1
2012
288
0.080
 Why?
Fractures, Spontaneous
1
2011
15
0.080
 Why?
Cyclohexanols
1
2011
9
0.080
 Why?
Hypercalcemia
1
2011
22
0.080
 Why?
Lung Neoplasms
2
2015
2664
0.080
 Why?
Nebulizers and Vaporizers
1
2011
62
0.080
 Why?
Child
6
2020
22707
0.080
 Why?
Drug Resistance, Neoplasm
2
2026
881
0.080
 Why?
Spinal Cord Compression
1
2011
24
0.080
 Why?
Cost Sharing
1
2011
20
0.080
 Why?
Sirolimus
1
2012
280
0.080
 Why?
Efficiency
2
2011
103
0.080
 Why?
Adamantane
1
2011
18
0.080
 Why?
Models, Statistical
2
2012
671
0.080
 Why?
Bone Diseases, Metabolic
1
2011
58
0.080
 Why?
Case-Control Studies
3
2014
3623
0.080
 Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2011
46
0.080
 Why?
Communication
1
2017
975
0.080
 Why?
Health Benefit Plans, Employee
2
2009
25
0.080
 Why?
Norepinephrine
1
2011
201
0.080
 Why?
Bone Neoplasms
1
2012
259
0.080
 Why?
Pyrazines
1
2011
94
0.080
 Why?
Pyrrolidines
1
2011
125
0.080
 Why?
Angiogenesis Inhibitors
1
2011
238
0.070
 Why?
Linear Models
1
2012
845
0.070
 Why?
Gastrointestinal Agents
1
2009
65
0.070
 Why?
Administration, Oral
1
2012
866
0.070
 Why?
Drug Utilization
1
2010
168
0.070
 Why?
Etanercept
1
2008
60
0.070
 Why?
Serotonin
1
2011
297
0.070
 Why?
Blood Chemical Analysis
1
2009
109
0.070
 Why?
Obesity
1
2022
3116
0.070
 Why?
Receptors, Tumor Necrosis Factor
1
2008
162
0.070
 Why?
Age Distribution
3
2015
403
0.070
 Why?
Depressive Disorder
1
2011
374
0.070
 Why?
Amphetamines
1
2007
6
0.070
 Why?
Adrenergic Uptake Inhibitors
1
2007
14
0.070
 Why?
Insurance, Pharmaceutical Services
1
2007
24
0.070
 Why?
Employment
2
2007
184
0.060
 Why?
Digestive System Surgical Procedures
1
2008
112
0.060
 Why?
Medical Audit
1
2007
77
0.060
 Why?
Quality-Adjusted Life Years
2
2022
123
0.060
 Why?
Age Factors
3
2015
3342
0.060
 Why?
Disease Progression
4
2015
2864
0.060
 Why?
Veterans Disability Claims
1
2006
4
0.060
 Why?
Algorithms
1
2014
1845
0.060
 Why?
Laboratories
1
2007
110
0.060
 Why?
Private Sector
1
2006
50
0.060
 Why?
Employer Health Costs
1
2005
4
0.060
 Why?
Coronary Disease
1
2008
381
0.060
 Why?
Ischemic Attack, Transient
1
2006
71
0.060
 Why?
Metabolic Diseases
1
2007
114
0.060
 Why?
Mexico
1
2026
233
0.060
 Why?
Hallucinations
1
2005
31
0.060
 Why?
Atrial Flutter
1
2005
47
0.060
 Why?
Asthma
2
2007
1797
0.050
 Why?
Double-Blind Method
4
2011
2062
0.050
 Why?
Area Under Curve
1
2005
331
0.050
 Why?
Administration, Inhalation
3
2011
571
0.050
 Why?
Diagnostic and Statistical Manual of Mental Disorders
1
2005
231
0.050
 Why?
Adrenal Cortex Hormones
1
2007
484
0.050
 Why?
Dasatinib
2
2014
58
0.050
 Why?
Metabolic Syndrome
1
2007
360
0.050
 Why?
Anti-Asthmatic Agents
1
2006
260
0.050
 Why?
Data Collection
1
2006
640
0.050
 Why?
Psychiatric Status Rating Scales
1
2005
531
0.050
 Why?
Body Weight
1
2007
971
0.050
 Why?
Colorectal Neoplasms
1
2011
866
0.050
 Why?
Lung
1
2015
4106
0.050
 Why?
Bevacizumab
2
2014
168
0.050
 Why?
Health Policy
1
2005
400
0.040
 Why?
Diagnosis, Differential
1
2006
1508
0.040
 Why?
Interviews as Topic
1
2005
910
0.040
 Why?
Dose-Response Relationship, Drug
3
2011
2028
0.040
 Why?
Veterans
1
2013
1635
0.040
 Why?
Glucagon-Like Peptides
1
2022
71
0.040
 Why?
Information Storage and Retrieval
1
2021
123
0.040
 Why?
Mental Health Services
1
2005
473
0.040
 Why?
Infant
4
2019
10077
0.040
 Why?
Hematopoietic Stem Cell Transplantation
1
2026
699
0.040
 Why?
Asia
1
2019
70
0.040
 Why?
Azacitidine
1
2021
157
0.040
 Why?
Remission Induction
2
2011
307
0.040
 Why?
France
1
2019
40
0.040
 Why?
Spain
1
2019
50
0.040
 Why?
Incidence
1
2006
2923
0.040
 Why?
Reproducibility of Results
1
2007
3413
0.040
 Why?
Italy
1
2019
116
0.040
 Why?
Germany
1
2019
138
0.040
 Why?
Cyclin-Dependent Kinase 4
1
2018
53
0.030
 Why?
Sex Factors
2
2015
2105
0.030
 Why?
Neutropenia
1
2018
154
0.030
 Why?
Potassium Channel Blockers
1
2017
47
0.030
 Why?
Disease Management
2
2015
653
0.030
 Why?
Models, Econometric
1
2016
34
0.030
 Why?
Bayes Theorem
1
2019
420
0.030
 Why?
Veterans Health
1
2018
190
0.030
 Why?
Itraconazole
1
2016
8
0.030
 Why?
B-Lymphocytes
1
2020
870
0.030
 Why?
Antineoplastic Protocols
1
2014
6
0.030
 Why?
Utilization Review
1
2014
39
0.030
 Why?
Cardiovascular Diseases
1
2007
2187
0.030
 Why?
Early Diagnosis
1
2015
251
0.030
 Why?
Forced Expiratory Volume
1
2015
450
0.030
 Why?
Gene Rearrangement
1
2015
155
0.030
 Why?
Aspergillus
1
2014
18
0.030
 Why?
Hypothyroidism
1
2014
67
0.030
 Why?
Genes, abl
1
2013
4
0.030
 Why?
Cryptococcus
1
2014
16
0.030
 Why?
Medication Therapy Management
1
2014
72
0.030
 Why?
Anemia, Iron-Deficiency
1
2014
62
0.030
 Why?
Peripheral Vascular Diseases
1
2014
104
0.030
 Why?
Socioeconomic Factors
1
2018
1323
0.020
 Why?
Mood Disorders
1
2014
143
0.020
 Why?
Drug Utilization Review
1
2013
61
0.020
 Why?
Myocardium
1
2018
934
0.020
 Why?
Acute Disease
1
2015
1036
0.020
 Why?
Propensity Score
1
2014
377
0.020
 Why?
Atenolol
1
2012
8
0.020
 Why?
Biopsy
1
2015
1082
0.020
 Why?
Nebivolol
1
2012
9
0.020
 Why?
Metoprolol
1
2012
26
0.020
 Why?
Propanolamines
1
2012
40
0.020
 Why?
Carbazoles
1
2012
53
0.020
 Why?
Risk
1
2014
919
0.020
 Why?
Decision Making
1
2019
977
0.020
 Why?
Matched-Pair Analysis
1
2011
37
0.020
 Why?
Nervous System Diseases
1
2014
286
0.020
 Why?
Duloxetine Hydrochloride
1
2011
10
0.020
 Why?
Venlafaxine Hydrochloride
1
2011
12
0.020
 Why?
Cetuximab
1
2011
111
0.020
 Why?
Sitagliptin Phosphate
1
2011
31
0.020
 Why?
Tablets
1
2010
41
0.020
 Why?
State Medicine
1
2009
26
0.020
 Why?
Length of Stay
1
2015
1349
0.020
 Why?
Epidemiologic Methods
1
2009
91
0.020
 Why?
Critical Care
1
2015
702
0.020
 Why?
Blood Glucose
2
2011
2341
0.020
 Why?
Injections, Subcutaneous
1
2009
170
0.020
 Why?
Maximum Tolerated Dose
1
2009
210
0.020
 Why?
Insurance Coverage
1
2010
244
0.020
 Why?
United Kingdom
1
2009
344
0.020
 Why?
Probability
1
2009
307
0.020
 Why?
Odds Ratio
1
2011
1082
0.020
 Why?
Statistics, Nonparametric
1
2009
428
0.020
 Why?
Confidence Intervals
1
2008
330
0.020
 Why?
Canada
1
2009
431
0.020
 Why?
Reference Values
1
2009
798
0.020
 Why?
Sex Distribution
1
2008
387
0.020
 Why?
Longitudinal Studies
1
2014
2953
0.020
 Why?
Prognosis
1
2015
4316
0.020
 Why?
Models, Biological
1
2014
1764
0.020
 Why?
Analysis of Variance
1
2009
1300
0.010
 Why?
RNA, Messenger
1
2013
2803
0.010
 Why?
Tomography, X-Ray Computed
1
2015
2769
0.010
 Why?
Health Status Disparities
1
2008
321
0.010
 Why?
Child, Preschool
2
2007
11853
0.010
 Why?
Emergency Medical Services
1
2007
684
0.010
 Why?
Risk Assessment
1
2009
3747
0.010
 Why?
Body Mass Index
1
2007
2445
0.010
 Why?
Infant, Newborn
1
2006
6447
0.010
 Why?
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (464) concept(s)
_
Co-Authors Expand Description
See all (2) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)